Cost-effectiveness analysis of minimally invasive surgical treatments for benign prostatic hyperplasia: implications for Japan’s public healthcare system

References

• Yoshida M, Flores NM, Vietri J, et al. Burden of benign prostatic hyperplasia among men in Japan: patient-reported outcomes among those diagnosed and experiencing symptoms. Int J Urol. 2015;22(10):949–955. doi: 10.1111/iju.12849.
   PubMed Web of Science ®Google Scholar
• Homma Y, Gotoh M, Yokoyama O, et al. JUA clinical guidelines for benign prostatic hyperplasia. Int J Urol. 2011;18(11):e1–e33. doi: 10.1111/j.1442-2042.2011.02861.x.
   Web of Science ®Google Scholar
• Homma Y, Gotoh M, Kawauchi A, et al. Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Int J Urol. 2017;24(10):716–729. doi: 10.1111/iju.13401.
   PubMed Web of Science ®Google Scholar
• Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease (GBD) Study 2019. Available from: https://vizhub.healthdata.org/gbd-results/
   Google Scholar
• Statistics Bureau of Japan. 2021 July Survey. 2021. Available from: https://www.stat.go.jp/english/
   Google Scholar
• The Japanese Urological Association (JUA). Clinical guidelines for male lower urinary tract symptoms and benign prostatic hyperplasia. Tokyo (Japan): RichHill Medical; 2017.
   Google Scholar
• Government of Japan Cabinet Office. The ageing society: current situation and implementation measures FY 2017. 2018. Available from: https://www8.cao.go.jp/kourei/english/annualreport/2018/pdf/c1-1.pdf
   Google Scholar
• Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173(4):1256–1261. doi: 10.1097/01.ju.0000155709.37840.fe.
   PubMed Web of Science ®Google Scholar
• Zhang AY, Xu X. Prevalence, burden, and treatment of lower urinary tract symptoms in men aged 50 and older: a systematic review of the literature. SAGE Open Nurs. 2018;4:2377960818811773.
   Google Scholar
• McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care. 2006;12(5 Suppl):S122–S128.
   PubMed Web of Science ®Google Scholar
• Soliman Y, Meyer R, Baum N. Falls in the elderly secondary to urinary symptoms. Rev Urol. 2016;18(1):28–32.
   PubMedGoogle Scholar
• Roehrborn CG, Marks L, Harkaway R. Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis. 2006;9(1):30–34. doi: 10.1038/sj.pcan.4500841.
   PubMed Web of Science ®Google Scholar
• Beckman TJ, Mynderse LA. Evaluation and medical management of benign prostatic hyperplasia. Mayo Clin Proc. 2005;80(10):1356–1362. doi: 10.4065/80.10.1356.
   PubMed Web of Science ®Google Scholar
• Emberton M, Cornel EB, Bassi PF, et al. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract. 2008;62(7):1076–1086. doi: 10.1111/j.1742-1241.2008.01785.x.
   PubMed Web of Science ®Google Scholar
• Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I, initial work-up and medical management. J Urol. 2021;206:806–817.
   Google Scholar
• Cindolo L, Pirozzi L, Fanizza C, et al. Drug adherence and clinical outcomes for patients under pharmacological therapy for lower urinary tract symptoms related to benign prostatic hyperplasia: population-based cohort study. Eur Urol. 2015;68(3):418–425. doi: 10.1016/j.eururo.2014.11.006.
   PubMed Web of Science ®Google Scholar
• McVary KT, Chughtai B, Miller LE, et al. Putting patients ahead by leaving nothing behind: an emerging treatment paradigm in minimally invasive surgical therapy for benign prostatic hyperplasia. Med Devices (Auckl). 2021;14:59–64. doi: 10.2147/MDER.S265237.
   PubMedGoogle Scholar
• Chung ASJ, Woo HH. Update on minimally invasive surgery and benign prostatic hyperplasia. Asian J Urol. 2018;5(1):22–27. doi: 10.1016/j.ajur.2017.06.001.
   PubMed Web of Science ®Google Scholar
• Dahm P, MacDonald R, McKenzie L, et al. Newer minimally invasive treatment modalities to treat lower urinary tract symptoms attributed to benign prostatic hyperplasia. Eur Urol Open Sci. 2021;26:72–82. doi: 10.1016/j.euros.2021.02.001.
   PubMedGoogle Scholar
• Harkaway RC, Issa MM. Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2006;9(3):204–214. doi: 10.1038/sj.pcan.4500869.
   PubMed Web of Science ®Google Scholar
• Bortnick E, Brown C, Simma-Chiang V, et al. Modern best practice in the management of benign prostatic hyperplasia in the elderly. Ther Adv Urol. 2020;12:1756287220929486. doi: 10.1177/1756287220929486.
   Web of Science ®Google Scholar
• McVary KT, Gittelman MC, Goldberg KA, et al. Final 5-year outcomes of the multicenter randomized Sham-controlled trial of a water vapor thermal therapy for treatment of moderate to severe lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2021;206(3):715–724. doi: 10.1097/JU.0000000000001778.
   PubMedGoogle Scholar
• Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. Can J Urol. 2017;24(3):8802–8813.
   PubMed Web of Science ®Google Scholar
• Tzeng M, Basourakos SP, Lewicki PJ, et al. New endoscopic in-office surgical therapies for benign prostatic hyperplasia: a systematic review. Eur Urol Focus. 2021;8(2):522–531. doi: 10.1016/j.euf.2021.02.013.
   PubMedGoogle Scholar
• Foster HE, Barry MJ, Dahm P, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol. 2018;200(3):612–619. doi: 10.1016/j.juro.2018.05.048.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Dahm P, Köhler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2020. J Urol. 2020;204(4):799–804. doi: 10.1097/JU.0000000000001298.
   PubMed Web of Science ®Google Scholar
• Chughtai B, Rojanasarot S, Neeser K, et al. Cost-effectiveness and budget impact of emerging minimally invasive surgical treatments for benign prostatic hyperplasia. J Health Econ Outcomes Res. 2021;8(1):42–50. doi: 10.36469/jheor.2021.22256.
   PubMedGoogle Scholar
• Chughtai B, Rojanasarot S, Neeser K, et al. A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. PLoS One. 2022;17(4):e0266824. doi: 10.1371/journal.pone.0266824.
   PubMed Web of Science ®Google Scholar
• McVary KT, Gange SN, Gittelman MC, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2016;195(5):1529–1538. doi: 10.1016/j.juro.2015.10.181.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. J Urol. 2013;190(6):2161–2167. doi: 10.1016/j.juro.2013.05.116.
   PubMed Web of Science ®Google Scholar
• Dixon CM, Cedano ER, Pacik D, et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. Res Rep Urol. 2016;8:207–216. doi: 10.2147/RRU.S119596.
   PubMed Web of Science ®Google Scholar
• Boston Scientific Corporation. Safety and efficacy study for the treatment of BPH (Enlarged Prostate) (REZUM): ClinicalTrials.gov Identifier: NCT01912339, 2020. 2023.
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Lower urinary tract symptoms in men: management – Clinical guideline [CG97] 2015 [cited 2023 Aug 9]. Available from: https://www.nice.org.uk/guidance/cg97
   Google Scholar
• Tallman CT, Zantek PF, Hernandez N, et al. Effectiveness of convective water vapor energy therapy versus prostatic urethral lift for symptomatic benign prostatic hyperplasia: a systematic review and indirect comparison. World J Urol. 2021;39(9):3207–3215. doi: 10.1007/s00345-021-03595-8.
   PubMed Web of Science ®Google Scholar
• Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691. doi: 10.1016/s0895-4356(97)00049-8.
   PubMed Web of Science ®Google Scholar
• 新医療機器の承認に関する情報. 新医療機器の承認に関する情報 2023.
   Google Scholar
• Ministry of Health, Labour and Welfare of Japan. Abridged life table. 2019. Available from: https://www.mhlw.go.jp/toukei/saikin/hw/life/life19/xlsx/life19-12.xlsx
   Google Scholar
• Ackerman SJ, Rein AL, Blute M, et al. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Urology. 2000;56(6):972–980. doi: 10.1016/s0090-4295(00)00828-1.
   PubMed Web of Science ®Google Scholar
• Bjerklund Johansen TE, Baker TM, Black LK. Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: a model based on the findings of the combination of avodart and tamsulosin trial. BJU Int. 2012;109(5):731–738. doi: 10.1111/j.1464-410X.2011.10511.x.
   PubMed Web of Science ®Google Scholar
• Cher DJ, Miyamoto J, Lenert LA. Incorporating risk attitude into Markov-process decision models: importance for individual decision making. Med Decis Making. 1997;17(3):340–350. doi: 10.1177/0272989X9701700311.
   PubMed Web of Science ®Google Scholar
• Chen HW, Bercik RS, Werner EF, et al. Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder. J Urol. 2012;187(1):178–184. doi: 10.1016/j.juro.2011.09.052.
   PubMed Web of Science ®Google Scholar
• Baladi J-F, Menon D, Otten N. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics. 1996;9(5):443–454. doi: 10.2165/00019053-199609050-00007.
   PubMed Web of Science ®Google Scholar
• Rognoni C, Tarricone R. Healthcare resource consumption for intermittent urinary catheterization: cost-effectivness of hydrophilic catheters and budget impact analysis. BMJ Open. 2017;7(1):e012360. doi: 10.1136/bmjopen-2016-012360.
   PubMed Web of Science ®Google Scholar
• Neotract I. Urolift system review report, PDMA 2018 [cited 2023 Aug 9]. Available from: https://www.pmda.go.jp/medical_devices/2018/M20181108001/index.html
   Google Scholar
• Japan Ministry of Health L, and Welfare. Health economic evaluation discount rate 2023. Available from: https://www.mhlw.go.jp/index.html
   Google Scholar
• Nakamura K. A “super-aged” society and the “locomotive syndrome”. J Orthop Sci. 2008;13(1):1–2. doi: 10.1007/s00776-007-1202-6.
   PubMed Web of Science ®Google Scholar
• Akiyama N, Shiroiwa T, Fukuda T, et al. Healthcare costs for the elderly in Japan: analysis of medical care and long-term care claim records. PLoS One. 2018;13(5):e0190392. doi: 10.1371/journal.pone.0190392.
   PubMed Web of Science ®Google Scholar
• Ogura H, Komoto S, Shiroiwa T, et al. Exploring the application of cost-effectiveness evaluation in the Japanese National Health Insurance System. Int J Technol Assess Health Care. 2019;35(6):452–460. doi: 10.1017/S0266462319000060.
   PubMed Web of Science ®Google Scholar
• Rojanasarot S, Cutone B, Durand K, et al. Patients’ perspectives on attributes while choosing minimally invasive surgery for benign prostatic hyperplasia procedures: experience from men undergoing water vapor thermal therapy. J Endourol. 2023;37(5):575–580. doi: 10.1089/end.2022.0607.
   PubMed Web of Science ®Google Scholar
• Chay J, Tung JYM, Su RJ, et al. Cost-effectiveness of alternative first- and second-line treatments for benign prostatic hyperplasia in Singapore. J Med Econ. 2023;26(1):1269–1277. doi: 10.1080/13696998.2023.2266958.
   PubMed Web of Science ®Google Scholar